Compliance as per Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the Quarter ended 31st March, 2026

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+5.7%1-day move

₹53.08

prior close

₹54.50

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.0+0.0+0.0+0.0+5.7+7.4+5.9+9.3+7.4+8.6+10.8+4.6-8.2-7.3

Up moveDown movePending

AI summary

Oxygenta Pharmaceutical Ltd has filed a routine quarterly compliance certificate confirming that details of securities dematerialized during Q4 FY 2025-26 (January-March 2026) have been submitted to BSE. The company's Registrar and Transfer Agent, Venture Capital and Corporate Investments Private Limited, certified that securities received for dematerialization were properly processed, mutilated, and cancelled within the 15-day regulatory timeline. The company's ISIN is INE102E01018 and scrip code is 524636. This is a standard regulatory filing with no material changes to share capital or shareholder structure.

Likely market impact

This is a routine compliance filing with no direct impact on the stock price or shareholder value. It confirms proper backend processing of dematerialization requests during the quarter.